<DOC>
	<DOCNO>NCT01410331</DOCNO>
	<brief_summary>This double-blind , placebo control study design evaluate safety efficacy JVS-100 give adult subject critical limb ischemia ( CLI ) .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy JVS-100 Administered Adults With Critical Limb Ischemia</brief_title>
	<detailed_description>48 subject diagnose Rutherford Class 4-5 Critical Limb Ischemia ( CLI ) non-healing ulcer and/or ischemic rest pain enrol study design investigate safety efficacy JVS-100 . JVS-100 deliver direct intramuscular injection limb study subject . Subjects randomize receive single set direct intramuscular injection either JVS-100 vehicle control follow 12 month post dose . Safety efficacy assessment collect 3 day , 4 week 3 , 6 12 month .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Men woman 40 year age old Rutherford Category 4 5 Ankle systolic pressure 70mmHg less , toe pressure 50mmHg less Poor option surgical revascularization open endovascular strategy Those diabetic subject optimal diabetes treatment , HbA1c &lt; 8.5 % Subject stable therapy treatment CLI , include statin antiplatelet therapy Subject must willing forgo treatment hyperbaric oxygen , nerve stimulation , ot sympathectomy treatment CLI 10 day prior 45 day follow injection study drug Life expectancy less 1 year Previous major amputation leg treat planned major amputation within first month follow enrollment Patent revascularization ( within 6 week ) leg treat prior enrollment NYHA Class IV heart failure Evidence osteomyelitis active infection Subjects Buerger 's Disease Subjects history Systemic Lupus Erythematosus ( SLE ) flare Subjects establish chronic kidney ( stage 5 ) require dialysis Uncontrolled blood pressure Significant hepatic disease Diabetic subject active proliferative retinopathy Immunodeficient state subject receive chronic immunosuppressive therapy Any patient history cancer unless 1 ) cancer limit curable nonmelanoma skin malignancy , 2 ) cancer remove successful tumor resection , without radiation chemotherapy , 5 year prior enrollment study without recurrence Pregnant lactate woman subject childbearing potential protected effective method birth control Men unwilling agree barrier contraception limit sexual activity Presence condition , opinion investigator , might compromise aspect trial Acute coronary syndrome within 3 month prior enrollment Previous treatment angiogenic growth factor stem cell therapy within 1 year Participation another clinical trial last 30 day Clinically significant elevation PT/PTT/INR Nonheel wound size &gt; 20 cm2 ( exclude toe gangrene ) heel wound size &gt; 10cm2 index limb History drug alcohol abuse last year</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>CLI</keyword>
	<keyword>peripheral vascular disease</keyword>
	<keyword>PVD</keyword>
	<keyword>PAD</keyword>
	<keyword>SDF-1</keyword>
</DOC>